1. Home
  2. KPTI vs BRIA Comparison

KPTI vs BRIA Comparison

Compare KPTI & BRIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • BRIA
  • Stock Information
  • Founded
  • KPTI 2008
  • BRIA 2011
  • Country
  • KPTI United States
  • BRIA Singapore
  • Employees
  • KPTI N/A
  • BRIA N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • BRIA
  • Sector
  • KPTI Health Care
  • BRIA
  • Exchange
  • KPTI Nasdaq
  • BRIA NYSE
  • Market Cap
  • KPTI 81.1M
  • BRIA 86.3M
  • IPO Year
  • KPTI 2013
  • BRIA 2024
  • Fundamental
  • Price
  • KPTI $0.63
  • BRIA $2.99
  • Analyst Decision
  • KPTI Strong Buy
  • BRIA
  • Analyst Count
  • KPTI 4
  • BRIA 0
  • Target Price
  • KPTI $5.00
  • BRIA N/A
  • AVG Volume (30 Days)
  • KPTI 694.6K
  • BRIA 30.7K
  • Earning Date
  • KPTI 02-27-2025
  • BRIA 02-19-2025
  • Dividend Yield
  • KPTI N/A
  • BRIA N/A
  • EPS Growth
  • KPTI N/A
  • BRIA N/A
  • EPS
  • KPTI N/A
  • BRIA 92.24
  • Revenue
  • KPTI $148,442,000.00
  • BRIA $55,755,669.00
  • Revenue This Year
  • KPTI $5.47
  • BRIA N/A
  • Revenue Next Year
  • KPTI $6.33
  • BRIA N/A
  • P/E Ratio
  • KPTI N/A
  • BRIA $0.03
  • Revenue Growth
  • KPTI 1.77
  • BRIA 8.03
  • 52 Week Low
  • KPTI $0.58
  • BRIA $2.90
  • 52 Week High
  • KPTI $1.70
  • BRIA $4.38
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 46.51
  • BRIA N/A
  • Support Level
  • KPTI $0.60
  • BRIA N/A
  • Resistance Level
  • KPTI $0.70
  • BRIA N/A
  • Average True Range (ATR)
  • KPTI 0.05
  • BRIA 0.00
  • MACD
  • KPTI -0.00
  • BRIA 0.00
  • Stochastic Oscillator
  • KPTI 46.61
  • BRIA 0.00

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About BRIA BRILLIA INC

BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.

Share on Social Networks: